Literature DB >> 4117275

Antinuclear antibodies in patients on anticonvulsant therapy.

D Alarcón-Segovia, E Fishbein, P A Reyes, H Díes, S Shwadsky.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1972        PMID: 4117275      PMCID: PMC1553649     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


× No keyword cloud information.
  21 in total

1.  SYSTEMIC LUPUS ERYTHEMATOSUS IN CHILDHOOD. REPORT OF THIRTY-FIVE CASES, WITH DISCUSSION OF SEVEN APPARENTLY INDUCED BY ANTICONVULSANT MEDICATION, AND OF PROGNOSIS AND TREATMENT.

Authors:  J C JACOBS
Journal:  Pediatrics       Date:  1963-08       Impact factor: 7.124

2.  Modern concepts of systemic lupus erythematosus; a review of 126 cases.

Authors:  J R HASERICK
Journal:  J Chronic Dis       Date:  1955-03

3.  Lupus erythematosus disseminatus after administration of mesantoin; report of two cases.

Authors:  T LINDQVIST
Journal:  Acta Med Scand       Date:  1957-08-13

4.  [L.E. phenomenon in two cases of drug hypersensitivity].

Authors:  P MIESCHER; J DELACRETAZ
Journal:  Schweiz Med Wochenschr       Date:  1953-06-06

5.  Systemic lupus erythematosus. Occurrence in association with ethosuximide therapy.

Authors:  S Livingston; H Rodriguez; C A Greene; L L Pauli
Journal:  JAMA       Date:  1968-05-20       Impact factor: 56.272

Review 6.  Drug-induced lupus syndromes.

Authors:  D Alarcón-Segovia
Journal:  Mayo Clin Proc       Date:  1969-09       Impact factor: 7.616

7.  Antibodies to nucleoprotein and to hydrazide-altered soluble nucleoprotein in tuberculous patients receiving isoniazid.

Authors:  D Alarcón-Segovia; E Fishbein; V M Betancourt
Journal:  Clin Exp Immunol       Date:  1969-10       Impact factor: 4.330

8.  The range and specificity of antinuclear antibodies in systemic lupus erythematosus.

Authors:  D Alarcón-Segovia; E Fishbein; H Alcalá; E Olguín-Palacios; S Estrada-Parra
Journal:  Clin Exp Immunol       Date:  1970-04       Impact factor: 4.330

9.  Activation of systemic lupus erythematosus by drugs.

Authors:  S L Lee; I Rivero; M Siegel
Journal:  Arch Intern Med       Date:  1966-05

10.  METHODS FOR THE PURIFICATION OF THYMUS NUCLEI AND THEIR APPLICATION TO STUDIES OF NUCLEAR PROTEIN SYNTHESIS.

Authors:  V G ALLFREY; V C LITTAU; A E MIRSKY
Journal:  J Cell Biol       Date:  1964-05       Impact factor: 10.539

View more
  9 in total

1.  Graft-versus-host reaction: a pathogenetic principle for the development of drug allergy, autoimmunity, and malignant lymphoma in non-chimeric individuals. Hypothesis.

Authors:  E Gleichmann; H Gleichmann
Journal:  Z Krebsforsch Klin Onkol Cancer Res Clin Oncol       Date:  1976-02-25

Review 2.  Drug-induced lupus anticoagulants and antiphospholipid antibodies.

Authors:  Jeffrey S Dlott; Robert A S Roubey
Journal:  Curr Rheumatol Rep       Date:  2012-02       Impact factor: 4.592

Review 3.  Immunoglobulins in epilepsy.

Authors:  J A Aarli
Journal:  Springer Semin Immunopathol       Date:  1985

4.  Lymphocytotoxins in epileptic patients receiving phenytoin.

Authors:  B S Ooi; K S Kant; I B Hanenson; A J Pesce; V E Pollak
Journal:  Clin Exp Immunol       Date:  1977-10       Impact factor: 4.330

5.  Carbamazepine induced systemic lupus erythematosus: case report.

Authors:  D E Bateman
Journal:  Br Med J (Clin Res Ed)       Date:  1985-09-07

6.  Morphological changes in the lymphoid organs induced by diphenylhydantoin sodium (DPH).

Authors:  I G Lorand; W A Hadler; L S Prigenzi
Journal:  Virchows Arch A Pathol Anat Histol       Date:  1976-11-22

Review 7.  Systemic lupus erythematosus (SLE)-like syndromes associated with carbamazepine therapy.

Authors:  K K Jain
Journal:  Drug Saf       Date:  1991 Sep-Oct       Impact factor: 5.606

Review 8.  Drug-induced antinuclear antibodies and lupus syndromes.

Authors:  D Alarcón-Segovia
Journal:  Drugs       Date:  1976       Impact factor: 9.546

9.  Complement activation by antibodies to Sm in systemic lupus erythematosus.

Authors:  U K Sabharwal; S Fong; S Hoch; R D Cook; J H Vaughan; J G Curd
Journal:  Clin Exp Immunol       Date:  1983-02       Impact factor: 4.330

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.